DR info

Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151

Polycystic kidney disease and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability

ID	Diseases (Sorted by drug repositionability)
67	Polycystic kidney disease
86	Pulmonary arterial hypertension
6	Parkinson disease
13	Multiple sclerosis/Neuromyelitis optica
96	Crohn disease
81	Congenital adrenal hyperplasia
58	Hypertrophic cardiomyopathy
75	Cushing disease
167	Marfan syndrome
46	Malignant rheumatoid arthritis
57	Idiopathic dilated cardiomyopathy
299	Cystic fibrosis
85	Idiopathic interstitial pneumonia
51	Scleroderma
97	Ulcerative colitis
89	Lymphangioleiomyomatosis
225	Congenital nephrogenic diabetes insipidus
113	Muscular dystrophy
74	Prolactin secreting pituitary adenoma
218	Alport syndrome
210	Single Ventricle
17	Multiple system atrophy
2	Amyotrophic lateral sclerosis
70	Spinal stenosis
127	Frontotemporal lobar degeneration
280	Huge arteriovenous malformation with cervicofacial or limb lesion
272	Fibrodysplasia ossificans progressiva
193	Prader-Willi syndrome
169	Menkes disease
170	Occipital horn syndrome
77	Growth hormone secreting pituitary adenoma
263	Cerebrotendinous xanthomatosis
28	Systemic amyloidosis
288	Autoimmune acquired coagulation factor deficiency
8	Huntington disease
34	Neurofibromatosis
78	Hypopituitarism
298	Hereditary pancreatitis
206	Fragile X syndrome
265	Lipodystrophy
222	Primary nephrotic syndrome
310	Congenital anomalies syndrome
158	Tuberous sclerosis
118	Myelomeningocele
49	Systemic lupus erythematosus
94	Primary sclerosing cholangitis
227	Osler disease
137	Focal cortical dysplasia
192	Cockayne syndrome
277	Lymphangiomatosis
281	Klippel-Trenaunay-Weber syndrome